India Globalization Capital Inc
Change company Symbol lookup
Select an option...
IGC India Globalization Capital Inc
NVAX Novavax Inc
EBIX Ebix Inc
FCRD First Eagle Alternative Capital BDC Inc
RWAY Runway Growth Finance Corp
LITB LightInTheBox Holding Co Ltd
UEC Uranium Energy Corp
NEE Nextera Energy Inc
MANT ManTech International Corp
AMPE Ampio Pharmaceuticals Inc
Go

Industrials : Trading Companies & Distributors | Small Cap Value
Company profile

India Globalization Capital, Inc. (IGC) is engaged in the development of cannabinoid-based therapies for indications such as Alzheimer's disease and pain. IGC operates through two segments: Life Sciences and Infrastructure. Life Sciences segment involves the development of potential new drugs, hand sanitizers and several hemp-based Cannabidiol (CBD) products and brands, wholesale of hemp extracts, including hemp crude extract and hemp isolate, among others, white labeling of hemp-based products, and offering of tolling services like extraction and distillation to hemp farmers. Infrastructure segment involves execution of construction contracts, rental of heavy construction equipment and purchase and resale of physical commodities used in infrastructure. IGC'S Life Sciences brands include Hyalolex, Holi Hemp, Holief, Herbo, and Sunday Seltzer.

Closing Price
$0.995
Day's Change
-0.005 (-0.50%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.02
Day's Low
0.97
Volume
(Light)
Volume:
195,868

10-day average volume:
325,969
195,868

Display:

Providers:

UpdateCancel
6 providers
December 14, 2021
Clinical Trial on Alzheimer's Patients Indicates Positive Safety and Tolerability Data for IGC's THC-Based Investigational New Drug

(NYSE American: IGC), India Globalization Capital, Inc. ("IGC" or the "Company") today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate...(BusinessWire)

December 08, 2021
Phase 1 Clinical Trial Provides Valuable Insights on Safe and Effective Dosing of IGC-AD1 for Alzheimer's Patients

(NYSE American: IGC), India Globalization Capital, Inc. (IGC) today announces preliminary results for its exploratory endpoints from its Phase 1 IGC-AD1 clinical trial. IGC-AD1 is a proprietary cannabis-based investigational new drug candidate for...(BusinessWire)

December 02, 2021
Phase 1 Clinical Trial Data Indicate IGC's THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer's Patients

(NYSE American: IGC), India Globalization Capital, Inc. (IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The investigational new drug, IGC-AD1, is IGC's proprietary...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.